Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA253038 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR1425070.fastq.gz | Fastqsanger.gz | |||
| SRR1425071.fastq.gz | Fastqsanger.gz | |||
| SRR1425072.fastq.gz | Fastqsanger.gz | |||
| SRR1425073.fastq.gz | Fastqsanger.gz | |||
| SRR1425074.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 12 |
Similar Datasets
Project description:Targeting “oncogene addiction” is a promising strategy for anti-cancer therapy. Here, we report a potent inhibition of crucial oncogenes by p53 upon reactivation with small molecule RITA in vitro and in vivo. RITA-activated p53 unleashes transcriptional repression of anti-apoptotic proteins Mcl-1, Bcl-2, MAP4, and survivin, blocks Akt pathway on several levels and downregulates c-Myc, cyclin E and B-catenin. p53 ablates c-Myc expression via several mechanisms at transcriptional and posttranscriptional level. We show that transrepression of oncogenes correlated with higher level of p53 bound to chromatin-bound p53 than transactivation of pro-apoptotic targets. Inhibition of oncogenes by p53 reduces the cell’s ability to buffer pro-apoptotic signals and elicits robust apoptosis. Our study highlights the role of transcriptional repression for p53-mediated tumor suppression. Experiment Overall Design: Breast carcinoma cell-line MCF7 was treated with the small-molecule p53 activator RITA for 2h, 8h, 16h and 24h.
2009-05-15 | E-GEOD-13291 | biostudies-arrayexpress
Project description:Small molecule-induced bioenergetic reprogramming directs prostate cancer inhibition via UPR signaling
| PRJNA208824 | ENA
Project description:The transcription factor FOXM1 binds to sequence-specific motifs on DNA (C/TAAACA) through its DNA binding domain (DBD), and activates proliferation- and differentiation-associated genes. Aberrant overexpression of FOXM1 is a key feature in oncogenesis and progression of many human cancers. Herein we identify novel inhibitors of FOXM1 that block DNA binding from a high-throughput screen applied to a library of 54,211 small molecules. One compound, FDI-6 (NCGC00099374) is studied in depth and is shown to bind directly to FOXM1 protein, displace the transcription factor from genomic targets in MCF-7 breast cancer cells, and induce concomitant transcriptional down-regulation. Global transcript profiling of MCF-7 cells by RNA-seq shows that FDI-6 specifically down regulates FOXM1-activated genes with FOXM1 occupancy confirmed by ChIP-seq. This small molecule mediated effect is selective for FOXM1-controlled genes with no effect on genes regulated by homologous forkhead family factors.
2014-08-15 | GSE58626 | GEO
Project description:Glioblastomas (GBM) are highly lethal tumors that are refractory to treatment. Here we describe a novel approach to target the epigenetic landscape of GBM and destabilize the glioma progenitor program, leading to inhibition of tumor growth. This is achieved through disruption of the activities of menin, an orphan protein that we demonstrate to play a pro-oncogenic role in GBM. Using pharmacologic and genetic tools, we identify HMGN1, a nucleosome binding chromatin architectural protein as a novel partner for menin. Disruption of this interaction via a newly designed small molecule mimics the major effects of knocking out MEN1, particularly leading to the suppression of H3K27 acetylation marks at genes critical for glioma progenitor identity, as well as promising therapeutic in vivo activity. This work demonstrates a novel role for menin as an epigenetic co-regulator of maintenance and proliferation of glioma.
2025-04-17 | GSE264271 | GEO
Project description:Glioblastomas (GBM) are highly lethal tumors that are refractory to treatment. Here we describe a novel approach to target the epigenetic landscape of GBM and destabilize the glioma progenitor program, leading to inhibition of tumor growth. This is achieved through disruption of the activities of menin, an orphan protein that we demonstrate to play a pro-oncogenic role in GBM. Using pharmacologic and genetic tools, we identify HMGN1, a nucleosome binding chromatin architectural protein as a novel partner for menin. Disruption of this interaction via a newly designed small molecule mimics the major effects of knocking out MEN1, particularly leading to the suppression of H3K27 acetylation marks at genes critical for glioma progenitor identity, as well as promising therapeutic in vivo activity. This work demonstrates a novel role for menin as an epigenetic co-regulator of maintenance and proliferation of glioma.
2025-04-17 | GSE264270 | GEO
Project description:Transcriptional profiling of a novel pro-angiogenic small molecule phthalimide neovascular factor 1 (PNF1)
| PRJNA119715 | ENA
Project description:A novel EMT-selective small molecule induces ER stress
| PRJNA240209 | ENA
Project description:FOXM1 transcription factor is an oncogene and a crucial regulator of cancer chemoresistance. Existing pharmacological FOXM1 inhibitors attenuate resistance of cancer cells to treatment but exhibit insufficient specificity. We performed in silico screening of small molecules from NIH LINCS database to identify STL427944 compound that suppresses FOXM1 through a novel two-step mechanism. STL427944 treatment induces relocalization of nuclear FOXM1 protein to cytoplasm, where it is subsequently degraded in an autophagosome-dependent manner. Human cancer cells treated with STL427944 exhibit increased sensitivity to cytotoxic effects of conventional chemotherapeutic agents. Transcriptome-based analysis of STL427944-induced gene expression changes revealed prominent suppression of gene signatures characteristic for FOXM1 and its downstream targets but no significant changes in other important regulatory pathways, thereby suggesting high selectivity of STL427944 towards FOXM1. We expect that STL427944 or its derivatives may be used in combination with different chemotherapeutical drugs to overcome tumor chemoresistance and improve anti-cancer treatment efficacy.
2021-07-21 | GSE162826 | GEO
Project description:Comparative analysis of the transcriptional response, as quantified by RNA-Seq, of Mycobacterium tuberculosis (Mtb) during inhibition of the terminal cytochrome oxidases, Cytochrome bd oxidase and Cytochrome bcc:aa3. This study was designed to evaluate the efficacy if a novel small molecule inhibitor of the Cytochrome bd oxidase. Specifically, we compared the transcriptional response of Mtb during inhibition by Q203 with a Cytochrome bd deletion mutant to the transcriptional response of Mtb treated with a combination of Q203 and the purported Cytorchomre bd small molecule inhibitor (ND-011992).
2020-10-07 | GSE159080 | GEO
Project description:Here we report the use of high-throughput sequencing technologies (RNA-seq, ChIP-seq) to identify the molecular programme of PBX1 and FOXM1 in multiple myeloma cells (MM1S, U266 cell lines). We performed Chromatin Immunoprecipitation followed by sequencing (ChIP-seq) against PBX1 in MM1S and U266 cells (n=2). In addition, we identifed the transcriptome of PBX1-depleted and FOXM1-depleted myeloma cells 3 days after transduction with shRNA-expressing lentiviral vectors. Molecular characterization revealed PBX1 as a novel epigenetic regulator of myeloma cell survival and proliferation. PBX1 directly and unilaterally controls the FOXM1 transcriptional programme and, together,they regulate the high-risk transcriptional signature of chr1q-amplified cells. Pharmacological inhibition of the unified PBX1-FOXM1 axis with thiostrepton showed selectivity against chr1q-amplified MM. Altogether, these data reveal PBX1-FOXM1 axis as a novel therapeutic avenue against chr1q-amplified MM.
2022-01-16 | GSE165060 | GEO